Ramasastry Saira

Ramasastry Saira’s Form 4 filings over the past year paint a clear picture: a steady seller with no open-market purchases. Across 39 transactions spanning two companies, Saira has disposed of roughly $1.85 million in stock, entirely through sales—most of them in Mirum Pharmaceuticals (MIRM). The pattern is consistent and mechanical: on or near the 15th of each month, Saira exercises options (code M) and immediately sells the resulting shares (code S). For instance, on June 1, 2026, a sale of $397,700 was the largest single disposition, while May 15 brought a $218,940 sale paired with a $47,020 option exercise. Smaller monthly sales of $181,000 to $204,000 occurred in January, February, March, and April 2026, each matched by identical option exercises—a cadence that suggests routine portfolio management rather than episodic decision-making. The remaining activity is largely non-discretionary. In late April 2026, Saira filed eight separate dispositions (code D) in DAWN, all valued at zero, indicating a return of shares to the issuer rather than cash-generating sales. June 2026 brought only compensation awards (code A) in both MIRM and Fathom Holdings (FTH), with no associated market transactions. Notably, there is not a single open-market purchase (code P) in the entire history, and the total buy value sits at zero. The only meaningful cash flows are the seven recent sales, all in MIRM, totaling roughly $1.78 million since December 2025. This is a one-directional pattern: Saira is monetizing equity holdings, not accumulating, with no recent buying bias to offset the steady stream of sell-side activity.